The global poultry medicine market size was estimated at USD 6.72 billion in 2024 and is projected to reach USD 11.90 billion by 2033, growing at a CAGR of 6.70% from 2025 to 2033. The market is advancing, driven by the growing prevalence of poultry diseases, rising demand for poultry products, and expansion of commercial poultry farming.
Key Market Trends & Insights
- The North American poultry medicine industry dominated the market with the largest revenue share of 37.42% in 2024.
- The poultry medicine industry in the U.S. is driven by avian influenza outbreaks and regulatory shifts away from antibiotics.
- Based on species, the chicken segment represented the largest revenue share of 72.50% in 2024.
- Based on product, the pharmaceuticals represented the largest segment in the market in terms of revenue share of 67.55% in 2024.
- Based on disease, the Newcastle disease was the largest disease segment with a share of 22.49% in 2024.
Market Size & Forecast
- 2024 Market Size: USD 6.72 Billion
- 2033 Projected Market Size: USD 11.90 Billion
- CAGR (2025-2033): 6.70%
- North America: Largest market in 2024
- Asia Pacific: Fastest growing market
Request For Sample Report @ https://www.grandviewresearch.com/industry-analysis/poultry-medicine-market-report/request/rs15
The frequent occurrence of poultry diseases like avian influenza, Newcastle disease, and infectious bronchitis has significantly increased the demand for effective pharmaceuticals. According to the Food and Agriculture Organization of U.S., as of April 2025, a total of 297 outbreaks or events of Highly Pathogenic Avian Influenza (HPAI) in poultry animals have been reported across five geographic regions.
Outbreaks of infectious diseases significantly impact poultry mortality and productivity. These recurrent health threats drive a strong demand for vaccines, antimicrobials, and antiparasitic treatments to protect flocks and reduce losses. Governments and producers are investing in better biosecurity and routine health management practices, creating consistent demand for poultry medicines. With the rise in intensive poultry farming and high bird densities, the risk of disease transmission grows, making regular medicinal interventions critical. This need for consistent health protection fuels steady growth in the market across all production scales.The World Organization for Animal Health (WOAH), an international body that sets global standards for animal health and monitors disease outbreaks to improve animal welfare and public health, conducted surveillance activities for Highly Pathogenic Avian Influenza (HPAI) in both poultry and non-poultry bird populations in the period of 2020-2023. The chart below illustrates the reporting of avian disease across various regions:
Key Poultry Medicine Company Insights
Leading players such as Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco, Ceva Santé Animale, and Virbac hold substantial portions of the market due to their diversified product portfolios, global distribution networks, and strong regulatory compliance. These companies continue to strengthen their positions through innovation in recombinant and vector-based vaccines, expansion into emerging markets, and strategic mergers and acquisitions. However, challenges such as regulatory complexities, high R&D costs, and growing restrictions on antibiotic use are reshaping the competitive landscape. Emerging players and regional firms are also gaining traction by offering affordable, targeted solutions suited for local disease profiles and resource-limited environments.
Key Poultry Medicine Companies:
The following are the leading companies in the poultry medicine market. These companies collectively hold the largest market share and dictate industry trends.
- Boehringer Ingelheim International GmbH
- Zoetis Services LLC
- Vaxxinova International BV
- Merck & Co., Inc.
- Calier
- Elanco
- Hester Biosciences Limited
- Ceva Santé Animale
- Phibro Animal Health Corporation
- Virbac
- Venkys India
- Calier
- Hipra
- Vetanco
- Kemin Industries, Inc
- Indovax
- Avimex
Recent Developments
- In June 2025, Boehringer Ingelheim announced the launch of a next-generation, single-dose poultry vaccine in India that protects against Bursal disease, Newcastle disease, and Marek’s disease.
- In November 2024, Ceva Animal Health launches Ceva Genesys, an innovative system for automatic, precise separation of male and female broilers at hatch, enhancing flock uniformity and overall production efficiency.
- In April 2024, Zoetis sold its medicated feed additive portfolio, select water-soluble products, and related assets to Phibro Animal Health, streamlining its focus on core veterinary innovations.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment